Contrasting effects of low-dose IL-2 on vaccine-boosted Simian Immunodeficiency Virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251

Journal of Immunology

Volumn 174, Issue 4, 2005, Pages 1913-1921

  Nacsa, Janos ^a   Edghill Smith, Yvette ^a   Tsai, Wen Po ^a   Venzon, David ^a   Tryniszewska, Elzbieta ^a,c   Hryniewicz, Anna ^a   Moniuszko, Marcin ^a,c   Kinter, Audrey ^b   Smith, Kendall A ^d   Franchini, Genoveffa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; GAG PROTEIN; INTERLEUKIN 2; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; STAVUDINE;

ANIMAL EXPERIMENT; ARTICLE; CANARYPOX VIRUS; CELL DEATH; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; T LYMPHOCYTE; VIRUS INFECTION;

EID: 13544254620     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.4.1913     Document Type: Article

References (66)

1. Davey, R. T., Jr., N. Bhat, C. Yoder, T. W. Chun, J. A. Metcalf, R. Dewar, V. Natarajan, R. A. Lempicki, J. W. Adelsberger, K. D. Miller, et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96:15109.
2. Ortiz, G. M., D. F. Nixon, A. Trkola, J. Binley, X. Jin, S. Bonhoeffer, P. J. Kuebler, S. M. Donahoe, M. A. Demoitie, W. M. Kakimoto, et al. 1999. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104:R13.
3. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991.
4. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8056.
5. + lymphocytes. Science 283:857.
6. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103.
7. + T cells in acute infectious mononucleosis. Nat. Med. 2:906.
8. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrew, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650.
9. Mongkolsapaya, J., A. Jaye, M. F. Callan, A. F. Magnusen, A. J. McMichael, and H. C. Whittle. 1999. Antigen-specific expansion of cytotoxic T lymphocytes in acute measles virus infection. J. Virol. 73:67.
10. Smith, K. A., M. F. Favata, and S. Oroszlan. 1983. Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics. J. Immunol. 131:1808.
11. Morgan, D. C., F. W. Ruscetti, and R. C. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007.
12. Cantrell, D. A., and K. A. Smith. 1984. The interleukin-2 T-cell system: a new cell growth model. Science 224:1312.
13. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240:1169.
14. Bassiri, H., and S. R. Carding. 2001. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J. Immunol. 166:5945.
15. Neilson, J. R., M. M. Winslow, E. M. Hur, and G. R. Crabtree. 2004. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 20:255.
16. Malek T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukocyte Biol. 74:961.
17. + T cell suppressor function. J. Immunol. 172:6519.
18. Arno, A., L. Ruiz, M. Juan, A. Jou, M. Balague, M. K. Zayat, S. Marfil, J. Martinez-Picado, M. A. Martinez, J. Romeu, et al. 1999. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J. Infect. Dis. 180:56.
19. + patients. Clin. Exp. Immunol. 120:101.
20. Davey, R. T. J., D. G. Chaitt, S. C. Piscitelli, M. Wells, J. A. Kovacs, R. E. Walker, J. Falloon, M. A. Polis, J. A. Metcalf, H. Masur, et al. 1997. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 175:781.
21. Davey, R. T. J., R. L. Murphy, F. M. Graziano, S. L. Boswell, A. T. Pavia, M. Cancio, J. P. Nadler, D. G. Chaitt, R. L. Dewar, D. K. Sahner, et al. 2000. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. J. Am. Med. Assoc. 284:183.
22. + subjects. J. Clin. Invest. 100:2737.
23. Emery, S., W. B. Capra, D. A. Cooper, R. T. Mitsuyasu, J. A. Kovacs, P. Vig, M. Smolskis, L. D. Saravolatx, H. C. Lane, G. A. Fyfe, and P. T. Curtin. 2000. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J. Infect. Dis. 182:428.
24. Hengge, U. R., M. Goos, S. Esser, V. Exner, H. Dotterer, H. Wiehler, C. Borchard, K. Muller, A. Beckmann, M. T. Eppner, et al. 1998. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 12:F225.
25. Kovacs, J. A., M. Baseler, R. J. Dewar, S. Vogel, R. T. J. Davey, J. Falloon, M. A. Polis, R. E. Walker, R. Stevens, and N. P. Salzman. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N. Engl. J. Med. 332:567.
26. Kovacs, J. A., S. Vogel, J. M. Albert, J. Falloon, R. T. Davey, Jr., R. E. Walker, M. A. Polis, K. Spooner, J. A. Metcalf, M. Baseler, et al. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350.
27. Larsen, C. S., L. Ostergard, B. K. Moller, and M. R. Buhl. 2000. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects. Scand. J. Infect. Dis. 32:153.
28. Levy, Y., C. Capitant, S. Houhou, I. Carriere, J. P. Viard, C. Goujard, J. A. Gastaut, E. Oksenhendler, L. Boumsell, E. Gomard, et al. 1999. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial: ANRS 048 study group. Lancet 353:1923.
29. 3. J. Infect. Dis. 181:1614.
30. Witzke, O., T. Winterhagen, W. Reinhardt, U. Heemann, H. Grosse-Wilde, E. Kreuzfelder, M. Roggendorf, and T. Philipp. 1998. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. J. Intern. Med. 244:235.
31. Smith, K. 2001. Interleukin 2 immunotherapy. In Therapeutic Immunology. F. Austen, S. Burakoff, F. Rosen, and T. Strom, eds. Blackwell Science, Malden, MA, p. 240.
32. Robb, R. J., A. Munck, and K. A. Smith. 1981. T cell growth factor receptors: quantitation, specificity, and biological relevance. J. Exp. Med. 154:1455.
33. Smith, K. A. 1989. The interleukin 2 receptor. Annu. Rev. Cell Biol. 5:397.
34. Caligiuri, M. A., A. Zmuidzinas, T. J. Manley, H. Levine, K. A. Smith, and J. Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171:1509.
35. Jacobson, E. L., F. Pilaro, and K. A. Smith. 1996. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93:10405.
36. Smith, K. A., E. L. Jacobson, R. Emert, M. Giordano, E. Kovacs, N. Mumneh, F. Pilaro, T. Sohn, and D. Warren. 1999. Restoration of immunity with interleukin-2 therapy. AIDS Read. 9:563.
37. + patients: a randomized controlled trial. HIV Clin. Trials 1:1.
38. Franchini, G. 2003. Modeling immune intervention strategies for HIV-1 infection of humans in the macaque model. Clin. Appl. Immunol. Rev. 3:289.
39. 251 infection of macaques. Nat. Med. 6:1140.
40. Tryniszewska, E., J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, et al. 2002. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169:5347.
41. Mills, K. H., and P. McGuirk. 2004. Antigen-specific regulatory T cells - their induction and role in infection. Semin. Immunol. 16:107.
42. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.
43. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101:455.
44. Shevach, E. M. 2000. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18:423.
45. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, and D. I. Watkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by PCR-SSP and direct sequencing. Tissue Antigens 50:657.
46. --induced immunodeficiency. J. Virol. 76:292.
47. + T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167:7180.
48. + T cell responses. J. Immunol. 169:4778.
49. Romano, J. W., K. G. Williams, R. N. Shurtliff, C. Ginocchio, and M. Kaplan. 1997. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26:15.
50. Smith, K. A. 2001. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 15(Suppl. 2):S28.
51. + patients treated with highly active antiretroviral therapy and interleukin 2. J. Clin. Immunol. 19:317.
52. high regulatory cells in human peripheral blood. J. Immunol. 167:1245.
53. Li, X. C., G. Demirci, S. Ferrari-Lacraz, C. Groves, A. Coyle, T. R. Malek, and T. B. Strom. 2001. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. 7:114.
54. Lenardo, M. J. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353:858.
55. Brunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echeverri, S. J. Martin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
56. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438.
57. Ju, S. T., D. J. Panka, H. Cui, R. Ettinger, M. el Khatib, D. H. Sherr, B. Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444.
58. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A. C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253.
59. Suzuki, H., G. S. Duncan, H. Takimoto, and T. W. Mak. 1997. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor β chain. J. Exp. Med. 185:499.
60. Willerford, D. M., J. Chen, J. A. Ferry, L. Davidson, A. Ma, and F. W. Alt. 1995. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521.
61. Blattman, J. N., J. M. Grayson, E. J. Wherry, S. M. Kaech, K. A. Smith, and R. Ahmed. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540.
62. + HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J. Exp. Med. 200:331.
63. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104:775.
64. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295.
65. + T cells. Nature 417:95.
66. Allen, T. M., J. Sidney, M. F. del Guercio, R. L. Glickman, G. L. Lensmeyer, D. A. Wiebe, R. DeMars, C. D. Pauza, R. P. Johnson, A. Sette, and D. I. Watkins. 1998. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160:6062.